Roger J. Waltzman

3.0k total citations · 1 hit paper
36 papers, 1.8k citations indexed

About

Roger J. Waltzman is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Roger J. Waltzman has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in Roger J. Waltzman's work include Erythropoietin and Anemia Treatment (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Roger J. Waltzman is often cited by papers focused on Erythropoietin and Anemia Treatment (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Roger J. Waltzman collaborates with scholars based in United States, United Kingdom and Switzerland. Roger J. Waltzman's co-authors include Jean‐Jacques Kiladjian, Claire Harrison, Deborah Hunter, Tiziano Barbui, Giovanni Barosi, Francisco Cervantes, Mari McQuitty, Viktoriya Stalbovskaya, Haifa Kathrin Al‐Ali and Laurent Knoops and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roger J. Waltzman

36 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

2012 1.2k citations Claire Harrison, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger J. Waltzman United States	12	1.2k	1.0k	658	431	368	36	1.8k
Tariq I. Mughal United States	21	788 0.7×	888 0.8×	463 0.7×	353 0.8×	430 1.2×	115	1.7k
Steven Fruchtman United States	20	1.1k 1.0×	1.1k 1.1×	528 0.8×	408 0.9×	133 0.4×	71	1.8k
Miklós Egyed Hungary	17	982 0.9×	1.1k 1.0×	806 1.2×	374 0.9×	318 0.9×	95	1.6k
Jorge Vela‐Ojeda Mexico	19	668 0.6×	1.1k 1.1×	258 0.4×	400 0.9×	346 0.9×	79	1.5k
Deepti Radia United Kingdom	17	1.0k 0.9×	736 0.7×	541 0.8×	567 1.3×	172 0.5×	87	1.7k
Vamsi Kota United States	19	397 0.3×	887 0.8×	397 0.6×	143 0.3×	408 1.1×	156	1.4k
Rolf Billström Sweden	25	473 0.4×	1.2k 1.2×	538 0.8×	156 0.4×	185 0.5×	58	1.7k
Mauro Fiacchini Italy	22	497 0.4×	966 0.9×	454 0.7×	190 0.4×	398 1.1×	57	1.5k
Gaëlle Guillerm France	18	527 0.5×	1.4k 1.3×	768 1.2×	208 0.5×	589 1.6×	66	1.8k
Markus Pfirrmann Germany	22	1.7k 1.5×	1.9k 1.9×	222 0.3×	967 2.2×	227 0.6×	71	2.5k

Countries citing papers authored by Roger J. Waltzman

Since Specialization

Citations

This map shows the geographic impact of Roger J. Waltzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger J. Waltzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger J. Waltzman more than expected).

Fields of papers citing papers by Roger J. Waltzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger J. Waltzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger J. Waltzman. The network helps show where Roger J. Waltzman may publish in the future.

Co-authorship network of co-authors of Roger J. Waltzman

This figure shows the co-authorship network connecting the top 25 collaborators of Roger J. Waltzman. A scholar is included among the top collaborators of Roger J. Waltzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger J. Waltzman. Roger J. Waltzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waltzman, Roger J., Diana L. Hanna, Angela Alistar, et al.. (2024). Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2583–2583. 3 indexed citations

Newman, Michael, et al.. (2023). 782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A1815–A1815. 2 indexed citations

Zodelava, Mamia, Troy H. Guthrie, Thomas Strack, et al.. (2020). A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 38(15_suppl). TPS8074–TPS8074. 3 indexed citations

Wainberg, Zev A., Minal Barve, Erika Hamilton, et al.. (2020). A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results.. Journal of Clinical Oncology. 38(15_suppl). e15567–e15567. 2 indexed citations

Kumar, Shaji, Robert F. Cornell, Ola Landgren, et al.. (2019). A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara). Blood. 134(Supplement_1). 1867–1867. 7 indexed citations

Harrison, Claire, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, et al.. (2012). JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine. 366(9). 787–798. 1218 indexed citations breakdown →

Kantarjian, Hagop M., Dong-Wook Kim, Surapol Issaragrisil, et al.. (2012). Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood. 120(21). 1676–1676. 30 indexed citations

Harrison, Claire, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, et al.. (2011). Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy. Blood. 118(21). 795–795. 2 indexed citations

Harrison, Claire, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, et al.. (2011). Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).. Journal of Clinical Oncology. 29(18_suppl). LBA6501–LBA6501. 22 indexed citations

10.

Guilhot, François, Brian Druker, Richard A. Larson, et al.. (2009). High rates of durable response are achieved with imatinib after treatment with interferon plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 94(12). 1669–1675. 41 indexed citations

11.

Hughes, Timothy P., Andreas Hochhaus, Susan Branford, et al.. (2008). Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Blood. 112(11). 334–334. 23 indexed citations

12.

Davidson, Brad, Diane Blum, David Cella, et al.. (2007). Communicating about chemotherapy-induced anemia.. PubMed. 5(1). 36–40, 46. 11 indexed citations

13.

Waltzman, Roger J., et al.. (2005). Final hematologic results: Epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT). Journal of Clinical Oncology. 23(16_suppl). 8030–8030. 7 indexed citations

14.

Waltzman, Roger J., Denise Williams, & Patricia S. Braly. (2005). A Pilot Study to Evaluate the Safety and Clinical Outcomes of Once-Weekly Epoetin Alfa 80,000 U in Anemic Patients with Cancer Receiving Chemotherapy. PubMed. 3(1). 47–53. 1 indexed citations

15.

Hamilton, Heidi E., et al.. (2005). Communication regarding chemotherapy-induced anemia and related fatigue: Recommendations from an observational linguistic study. Journal of Clinical Oncology. 23(16_suppl). 8047–8047. 2 indexed citations

16.

Waltzman, Roger J., et al.. (2004). Managing hematologic toxicities.. PubMed. 2(1). 65–79. 8 indexed citations

17.

Waltzman, Roger J.. (2004). Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms. Seminars in Hematology. 41(4 Suppl 7). 9–16. 6 indexed citations

18.

Hensley, Martee L., Larry Léon, Ennapadam Venkatraman, et al.. (2001). Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer. Gynecologic Oncology. 81(3). 485–489. 11 indexed citations

19.

Casper, Ephraim S., Roger J. Waltzman, Gary K. Schwartz, et al.. (1998). Phase II Trial of Paclitaxel in Patients with Soft-Tissue Sarcoma. Cancer Investigation. 16(7). 442–446. 88 indexed citations

20.

Aghajanian, Carol, D. Fennelly, F.L. Shapiro, et al.. (1998). Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.. Journal of Clinical Oncology. 16(5). 1852–1860. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact